Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
Jin Hee Shin,1 Kishore M Gadde2 1Department of Community and Family Medicine, Duke University Medical Center, 2Obesity Clinical Trials Program, Duke University Medical Center, Durham, NC, USA Abstract: Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-re...
Enregistré dans:
Auteurs principaux: | Shin JH, Gadde KM |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/8e7b8c78bbcb44519fdfc944b618afb1 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
par: Sweeting AN, et autres
Publié: (2014) -
Effects of Orlistat/Phentermine versus Phentermine on Vascular Endothelial Cell Function in Obese and Overweight Adults: A Randomized, Double-Blinded, Placebo-Controlled Trial
par: Kwon YJ, et autres
Publié: (2021) -
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
par: Karen Barnard, et autres
Publié: (2010) -
Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
par: Maffioli P, et autres
Publié: (2011) -
The clinical utility of aflibercept for diabetic macular edema
par: Stewart MW
Publié: (2015)